Refine
Year of publication
Document Type
- Preprint (366)
- Article (204)
- Doctoral Thesis (2)
- Part of a Book (1)
- Report (1)
Has Fulltext
- yes (574)
Is part of the Bibliography
- no (574)
Keywords
- Heavy Ion Experiments (11)
- Hadron-Hadron scattering (experiments) (7)
- Hadron-Hadron Scattering (3)
- Heavy-ion collision (3)
- COVID-19 surveillance (2)
- Charm physics (2)
- Diagnostik (2)
- Früherkennung (2)
- Heavy Ions (2)
- LHC (2)
Institute
- Physik (546)
- Frankfurt Institute for Advanced Studies (FIAS) (509)
- Informatik (490)
- Medizin (19)
- Biochemie, Chemie und Pharmazie (4)
- Biowissenschaften (3)
- Hochschulrechenzentrum (2)
- Biochemie und Chemie (1)
- Universitätsbibliothek (1)
The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections. We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R. We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 8.00 and 5.33, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.51-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab. In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which, however, might be circumvented by combination therapy with casirivimab together.
The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections.
We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R.
We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 8.00 and 5.33, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.5-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab.
In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which however, might be circumvented by a combination therapy with casirivimab together.
Bericht der Arbeitsgruppe Technik zur Vorbereitung des Programms "Retrospektive Digitalisierung von Bibliotheksbeständen" im Förderbereich "Verteilte Digitale Forschungsbibliothek" Arbeitssitzungen am 14. Mai 1996 (Frankfurt a. M.), 29.-30. Juli 1996 (München), 12.-13. Dezember 1996 (Göttingen) Mitglieder der Arbeitsgruppe: Prof. Dr. Rudolf Bayer, Technische Universität München, Fakultät für Informatik Dr. Jürgen Bunzel, Deutsche Forschungsgemeinschaft, Bonn Dr. Marianne Dörr, Bayerische Staatsbibliothek München Dr. Reinhard Ecker, Beilstein-Institut bzw. ABC Datenservice GmbH, Frankfurt/Main Dipl.-Math. Heinz-Werner Hoffmann, Hochschulbibliothekszentrum NRW, Köln (als Gast für die AG der Verbundsysteme) Dr. Norbert Lossau, Niedersächsische Staats- und Universitätsbibliothek Göttingen (DFG-Projekt ‘Verteilte Digitale Forschungsbibliothek’) Prof. Dr. Elmar Mittler, Niedersächsische Staats- und Universitätsbibliothek Göttingen Dipl.-Inf. Christian Mönch, FB Informatik der J.W. Goethe-Universität Frankfurt Dr. Wilhelm R. Schmidt, Stadt- und Universitätsbibliothek Frankfurt Dr. Hartmut Weber, Landesarchivdirektion, Stuttgart
A wide variety of enzymatic pathways that produce specialized metabolites in bacteria, fungi and plants are known to be encoded in biosynthetic gene clusters. Information about these clusters, pathways and metabolites is currently dispersed throughout the literature, making it difficult to exploit. To facilitate consistent and systematic deposition and retrieval of data on biosynthetic gene clusters, we propose the Minimum Information about a Biosynthetic Gene cluster (MIBiG) data standard.